Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: Mike who wrote (690)	10/21/1999 10:08:00 AM
From: Lighthouse	Read Replies (1) \| Respond to of 798

Bit of mixed bad it appears. From the 1998 Annual Report, "As average selling prices for the NIR stents fluctuate, the Company's cost to purchase the stents will change because cost is based on a constant percentage of average selling prices." F-2 Annual Report However, there is a base commitment to purchase $150 million in stents from Medinol over the course of 1999. The number for 2000 is not disclosed. If the NIR loses ground vis-a-vis GDT, MDT, and JNJ in 2000 then I imagine BSX will have some talks with Medinol about the supply commitment. Cheers